Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Frontiers in Immunology|September 13, 2012
Autoimmune dysregulation and purine metabolism in adenosine deaminase deficiencyAisha Vanessa Sauer, Immacolata Brigida, Nicola Carriglio, et al.Current Opinion in Allergy and Clinical Immunology|September 11, 2014
Progress in gene therapy for primary immunodeficiencies using lentiviral vectorsAisha V Sauer, Biagio Di Lorenzo, Nicola Carriglio, et al.Human Gene Therapy|September 5, 2020
Conditioning Regimens in Long-Term Pre-Clinical Studies to Support Development of <i>Ex Vivo</i> Gene Therapy: Review of Nonproliferative and Proliferative ChangesFranck J A Chanut, Francesca Sanvito, Giuliana Ferrari, et al.Human Gene Therapy. Clinical Development|March 21, 2017
Good Laboratory Practice Preclinical Safety Studies for GSK2696273 (MLV Vector-Based Ex Vivo Gene Therapy for Adenosine Deaminase Deficiency Severe Combined Immunodeficiency) in NSG MiceNicola Carriglio, Jan Klapwijk, Raisa Jofra Hernandez, et al.Blood|December 21, 2011
Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCIDAisha V Sauer, Immacolata Brigida, Nicola Carriglio, et al.Life Science Alliance|February 16, 2022
mRNA COVID-19 vaccine booster fosters B- and T-cell responses in immunocompromised patientsElena Azzolini, Chiara Pozzi, Luca Germagnoli, et al.Molecular Therapy : the Journal of the American Society of Gene Therapy|October 3, 2020
Hematopoietic Tumors in a Mouse Model of X-linked Chronic Granulomatous Disease after Lentiviral Vector-Mediated Gene TherapyRaisa Jofra Hernández, Andrea Calabria, Francesca Sanvito, et al.Scientific Reports|January 12, 2017
Alterations in the brain adenosine metabolism cause behavioral and neurological impairment in ADA-deficient mice and patientsAisha V Sauer, Raisa Jofra Hernandez, Francesca Fumagalli, et al.Pageof 1